Description
Rydapt (midostaurin) is an oral medication prescribed with other treatments for adults with newly diagnosed acute myeloid leukemia (AML). It is also used to treat adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).
Rydapt is available in 25 mg capsules.
Fact Table |
Formula |
C35H30N4O4 |
License |
US FDA, EMA |
Bioavailability |
57% |
Legal status |
Prescription only |
Chemical Name |
Midostaurin |
Elimination half-life |
20-40 hours |
Dosage (Strength) |
25 mg capsules |
Pregnancy |
Consult a doctor |
Brands |
Rydapt |
Protein binding |
98% |
PubChem CID |
9576885 |
MedlinePlus |
a617037 |
ChEBI |
63630 |
ATC code |
L01XE39 |
DrugBank |
DB09073 |
KEGG |
D10561 |
Routes of administration |
Oral |
Directions
Take Rydapt exactly as prescribed by your doctor. Carefully read the medication guide that comes with your prescription.
Recommended dosing for AML: 50 mg by mouth two times a day with food.
Recommended dosing for ASM, SM-AHN, and MCL: 100 mg by mouth two times a day with food.
Rydapt storage: Keep Rydapt capsules in their original container at room temperature between 68°F and 77°F (20°C and 25°C). Keep the medication out of reach of children.
If you have any questions or concerns about Rydapt, talk to your doctor or pharmacist.
Ingredients
The active ingredient in Rydapt is midostaurin.
Inactive ingredients include carmine, corn oil mono-di-triglycerides, dehydrated alcohol, ferric oxide red, ferric oxide yellow, gelatin, glycerin 85%, hypromellose 2910, polyethylene glycol 400, polyoxyl 40 hydrogenated castor oil, propylene glycol, purified water, titanium dioxide, and vitamin E.
Contraindications
Patients who are allergic to Rydapt or to any of its ingredients should not take it.
Cautions
- Before you start taking Rydapt, tell your doctor about:
- All the prescription and over-the-counter medications you take
- Your allergies
- Your current health problems and past medical history
- Your pregnancy or breastfeeding status
- Rydapt may cause harm to an unborn baby. Effective contraception is recommended for females of childbearing age and males with female partners who are of childbearing age during treatment with Rydapt and for 4 months after taking the final dose.
- Rydapt may cause pulmonary toxicity that can be fatal.
- Breastfeeding is not recommended.
Side Effects
Low white blood cell counts, nausea, sore or inflamed mouth or gut, vomiting, headache, bleeding spots under the skin, musculoskeletal pain, nose bleeds, device-related infection, high blood glucose, abnormal heart rhythms, upper respiratory tract infections, swelling, fatigue, constipation, shortness of breath, and fever are some common side effects associated with Rydapt. However, other side effects may also occur. Immediately inform your doctor of any side effects that bother you or won’t go away.
Searching for a competitive Rydapt 25 mg price? You can buy Rydapt right here!
Reference:
Rydapt. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
About Dr. Savannah Muncy (Page Author)
Dr. Muncy (PharmD) studied science and education as an undergraduate before attending the Appalachian College of Pharmacy where she completed her PharmD in three years. She is currently using her pharmacy and healthcare expertise to write medical content for clients all around the world. She is focused on delivering the most current, accurate, and engaging information to healthcare professionals and patients. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14552